FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC OncLive
Regulatory Approvals
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC CancerNetwork
FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in Food
The U.S. Food and Drug Administration today announced two actions targeting petroleum-based color additives in food, continuing the agency’s broader…
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC Targeted Oncology
Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer
Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer simplywall.st